Sign inJoin waitlistJoin the waitlist

Daniela Matei

Division Chief · McGaw Medical Center of Northwestern University

Credentials: · · · ·

History

McGaw Medical Center of Northwestern University
Present
Reproductive Science in Medicine Division · McGaw Medical Center of Northwestern University
Present
McGaw Medical Center of Northwestern University
Present

University of California-Los Angeles
2000–2002
Hematology and Medical Oncology
UCLA David Geffen School of Medicine/UCLA Medical Center
1999–2002
Internal Medicine
Stony Brook Medicine
1993–1996
Anesthesiology
SUNY Downstate Health Sciences University
1992–1996
Carol Davila University of Medicine and Pharmacy -
1988–1992
Medicine | University of Medicine and Pharmacy Carol Davila
1989–1992

Research

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
New England Journal of Medicine · 2012 · 1,485 citations
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised…
The Lancet Oncology · 2014 · 1,155 citations
Identification and characterization of ovarian cancer-initiating cells from primary human tumors
Cancer Research · 2008 · 1,056 citations

Ursula Matulonis
12 papers
Robert Emerson
11 papers
David Miller
8 papers
ET
Edward Tanner
8 papers
Emma Barber
8 papers
Gini Fleming
8 papers
JS
Jeanne Schilder
8 papers
Jian-Jun Wei
7 papers
YZ
Yaqi Zhang
7 papers · 7 as a resident
Deborah Armstrong
6 papers
Angela Jain
5 papers
David Gershenson
5 papers

Grants

Northwestern University Lead Academic Participating Site
National Cancer Institute · UG1
PI · $1.5M · Northwestern University
2026–2032
Lipid Unsaturation Drives Ovarian Cancer Progression
National Cancer Institute · R01
Contact PI · $3.6M · Methodist Hospital Research Institute
2018–2031
The Robert H. Lurie Comprehensive Cancer Center
National Cancer Institute · P30
Project lead · $168.4K · Northwestern University
1997–2030
Understanding Metabolic Reprogramming in Platinum Resistant Ovarian Cancer
Department of Veterans Affairs · I01
Contact PI · Jesse Brown Va Medical Center
2022–2027

Clinical trials

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Principal investigator · Completed · Phase 2
Northwestern University
2021
Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Principal investigator · Completed · Phase 2
Northwestern University
2016–2023
Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Principal investigator · Completed · Phase 2
Northwestern University
2013–2021
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Principal investigator · Withdrawn · Phase 1, Phase 2
Hoosier Cancer Research Network
2012–2014